Trinity Biotech plc (TRIB)
Nasdaq · Healthcare · Medical Devices
$5.77+1.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $4.7M
- 52-week range
- $5.01 – $52.50
- 52-week change
- −82.27%
- EPS (trailing)
- −$60.00
About Trinity Biotech plc
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
Headquarters: Bray, Ireland · 287 employees · trinitybiotech.com